Roche Holding AG EBITDA 2010-2023 | RHHBY
Roche Holding AG annual and quarterly EBITDA history from 2010 to 2023. EBITDA can be defined as earnings before interest, taxes, depreciation and amortization.
- Roche Holding AG EBITDA for the quarter ending December 31, 2023 was $M, a NAN% increase year-over-year.
- Roche Holding AG EBITDA for the twelve months ending December 31, 2023 was $0M, a NAN% increase year-over-year.
- Roche Holding AG 2023 annual EBITDA was $21.007B, a 5.97% decline from 2022.
- Roche Holding AG 2022 annual EBITDA was $22.341B, a 9.64% decline from 2021.
- Roche Holding AG 2021 annual EBITDA was $24.724B, a 0.34% increase from 2020.
Roche Holding AG Annual EBITDA
(Millions of US $) |
| 2023 |
$21,007 |
| 2022 |
$22,341 |
| 2021 |
$24,724 |
| 2020 |
$24,640 |
| 2019 |
$21,982 |
| 2018 |
$18,766 |
| 2017 |
$17,165 |
| 2016 |
$14,284 |
| 2015 |
$14,384 |
| 2014 |
$15,419 |
| 2013 |
$17,678 |
| 2012 |
$15,073 |
| 2011 |
$17,915 |
| 2010 |
$11,332 |
| 2009 |
$11,926 |
Roche Holding AG Quarterly EBITDA
(Millions of US $) |
| 2023-12-31 |
|
| 2022-12-31 |
|
| 2022-06-30 |
|
| 2021-12-31 |
|
| 2021-06-30 |
|
| 2020-12-31 |
|
| 2020-06-30 |
|
| 2019-12-31 |
|
| 2019-06-30 |
|
| 2018-12-31 |
|
| 2018-06-30 |
|
| 2017-12-31 |
|
| 2017-06-30 |
|
| 2016-12-31 |
|
| 2016-06-30 |
|
| 2015-12-31 |
|
| 2015-06-30 |
|
| 2014-12-31 |
|
| 2014-06-30 |
|
| 2013-12-31 |
|
| 2013-06-30 |
|
| 2012-12-31 |
|
| 2012-06-30 |
|
| 2011-12-31 |
|
| 2011-06-30 |
|
| 2010-12-31 |
|
| 2010-06-30 |
|
| 2009-12-31 |
|
| 2009-06-30 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$231.838B |
$65.370B |
|
Basel, Switzerland-based Roche Holding Ltd. is a leading health care company focused on developing and commercializing innovative diagnostic and therapeutic products and services, which enable early detection and prevention of diseases as well as their treatment and monitoring. The company conducts its operations through two segments ' Pharmaceuticals and Diagnostics.Pharmaceuticals: Key focus areas in this segment include Oncology, Virology, Inflammation, Metabolism and Neuroscience. Diagnostics: The Diagnostics Division operates in four segments ' Roche Professional Diagnostics, Roche Diabetes Care, Roche Molecular Diagnostics, and Roche Tissue Diagnostics. In September 2014, Roche acquired InterMune for $8.3 billion and added Esbriet to its portfolio. During the first quarter of 2018, Roche acquired Flatiron Health and Ignyta, Inc.
|
